Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-Center, Non-Comparative Study to Evaluate the Contraceptive Efficacy, Safety, and Tolerability of LPRI-CF113 Administered Orally for 13 Medication Cycles

NCT05461573 is registered in ClinicalTrials.gov with Insud Pharma as lead sponsor.

NCT NCT05461573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05461573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-Center, Non-Comparative Study to Evaluate the Contraceptive Efficacy, Safety, and Tolerability of LPRI-CF113 Administered Orally for 13 Medication Cycles
Lead sponsor
Insud Pharma
Phase
Phase 3
Overall status
Completed
Start date
August 2, 2022
Completion date
May 27, 2025
Enrollment
1,542 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

change in bone mineral density, contraception